AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 2385 businesses audited.
Unclear / Mixed / Unclassifiable Industry BS: TRODELVY (Gilead Sciences, Inc.) (trodelvy.com)
This site is the antithesis of bullshit. It functions as a clinical data repository where every marketing claim is legally and scientifically anchored to Phase 3 trial results. The only ‘points’ earned are for the lack of structured identity data (Schema) and the inherent repetition required by pharmaceutical regulations.
Implement Organization and Product JSON-LD schema to provide search engines with a verified link to Gilead Sciences and regulatory status. Replace the ‘Actor portrayal’ disclaimer on the ‘How it Works’ video with a dual-track approach that includes verifiable commentary from the actual clinical researchers. Ensure all clinical trial citations link directly to the peer-reviewed publications (e.g., NEJM or ASCO) rather than just internal summaries. Maintain the current ratio of data-to-text, as it is the primary driver of the low BS score.
The site exhibits extremely high substance-to-fluff ratios. Unlike typical corporate sites, the body text is packed with forensic data points such as median overall survival (14.4 months vs 11.2 months for HR+/HER2- mBC) and specific clinical trial participant counts (n=543 and n=529). Fluff-heavy power words are almost non-existent in headings, which prioritize descriptive clinical functions like [H3] Important Safety Information and [H2] TRODELVY targets cells with Trop-2.
When multiple URL variants exist, AI generates multiple embeddings of the same page. Run a Canonical Identity Stability Audit to see whether your site resolves into a single authoritative version.
There is zero detectable semantic drift between the homepage and sub-pages. The homepage establishes the two primary indications (mTNBC and HR+/HER2- mBC), and the sub-pages provide granular Phase 3 clinical data that directly supports those claims. The messaging remains clinical, transparent, and consistent across all examined slots.
Identify the current state and friction diagnosis of your specific business model. Generate your Executive SEO Strategy to quantify the financial or conversion cost of strategic misalignment.
The site avoids trust theatre entirely; there are no unverified five-star review widgets or generic ‘trusted by’ logos. Instead, it provides a 0 review_count but offsets this with high-authority proof paths to the FDA MedWatch program and specific Phase 3 clinical trial citations. Performance claims regarding survival are not presented as ‘results may vary’ fluff but as statistically significant median outcomes from controlled studies.
Proof density is exceptionally high, with 8+ instances of specific evidence (months of survival, trial sizes, molecular targets) found across all sub-pages. Every primary claim regarding drug efficacy is accompanied by a footnote or a dedicated results section detailing the Phase 3 trial parameters.
For a demonstration of entity driven retail architecture, open the Walmart Structured Data audit. View the Walmart Structured Data Audit to see how product, brand, and service entities are reconstructed for AI systems.
The fingerprint is minimal because the value proposition is tied to a specific chemical entity (sacituzumab govitecan-hziy) rather than generic service cliches. The only match to the patterns dictionary is the phrase ‘designed differently,’ but this is immediately qualified by a technical explanation of Antibody-Drug Conjugate (ADC) technology. No generic ‘Why Choose Us’ or ‘World Class’ templates are used.
The primary gap is technical rather than rhetorical, as the schema_json is null across all pages, missing an opportunity to link the brand to Gilead Sciences via Organization schema. While the site features a ‘Dr. Esposito,’ it transparently labels the content as ‘Actor portrayals,’ which prevents a penalty for deceptive authority but lacks a direct link to the real medical researchers behind the drug.
There is no disconnect between marketing tone and demonstrated evidence. The site claims the drug helps people live longer and immediately provides the delta in months (e.g., a 4.9-month improvement in median overall survival for mTNBC) to prove it. These are not ‘bold performance claims’ in a marketing sense but ‘verifiable clinical outcomes.’
Unclear / Mixed / Unclassifiable Industry BS: TRODELVY (Gilead Sciences, Inc.) (trodelvy.com)
The website is a textbook example of a regulated pharmaceutical product site. It aligns perfectly with the oncology sector, providing high-density clinical data, mandatory safety disclosures, and specific patient indications.
Your site's meaning is determined by its graph, not its menus. Review the Internal Linking Architecture Framework to see how AI interprets nodes, edges, and authority flow inside your domain.
“The score of 10 is driven primarily by the 'Identity and Authority' pillar (7/15) due to the absence of technical schema and the use of actor portrayals in place of named clinical authorities. All other pillars scored near zero due to the site's extreme reliance on verifiable clinical metrics and its complete avoidance of industry jargon or generic marketing templates.”
Analysis Disclosure & Source Attribution
Snapshot Date: June 20, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at TRODELVY (Gilead Sciences, Inc.) to view the most current version of their content and see directly what the company offers.